A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi
A phase 3 trial of Sotorasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, now recruiting.
Overview
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) is a phase 3 interventional study registered as NCT05920356 by Amgen, with 750 participants planned, started 2023-11-16 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sotorasib, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Shares Amgen, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Shares Amgen, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Shares Sotorasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal
- TrialA Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Shares Amgen, Small-cell lung cancer.